[Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus].
The recent ACCORD and DIAD studies revealed results which could modify treatments and the screening of diabetes vascular complications. Indeed, ACCORD shows no benefit on the prevention of diabetes vascular complications by aggressive treatment of hypertension or the combined treatment of the dyslipidemia. The intensive treatment of the blood glucose, if associated with severe hypoglycemias, increases mortality. DIAD revealed 20% of silent myocardial ischaemia in diabetic patients but no beneficial effect on the cardiovascular mortality. A careful reading of these studies in the light of long term studies such as UKPDS and STENO reveals that these negative results are generated by a too short follow-up and too aggressive objectives. The long term studies reveal that more realistic objectives remain beneficial.
Ruiz
J
J
Service d'endocrinologie, diabétologie et métabolisme, CHUV et Université de Lausanne. juan.ruiz@chuv.ch
Egli
M
M
Gianinazzi
F
F
Izzo
F
F
Voeffray Favre
A C
AC
Rossi
I
I
Bodenman
P
P
D003327:Coronary Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy; D019317:Evidence-Based Medicine; D011345:Fenofibrate / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008403:Mass Screening; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D000960:Hypolipidemic Agents; D011345:Fenofibrate